Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROP2-CAR-NK Cells + Cetuximab in MRD Colorectal Cancer
NCT06358430Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2024
- Primary completion
- Jan 2029
- Modality
- CAR-T Cells, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TROP2-CAR-NK in colorectal cancer (CRC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and adverse events at 1 year, Maximum Tolerated Dose and Recommended Phase 2 Dose at 1 year and 1 more. Started Dec 2024; status: active, not recruiting.
02
Drugs
TROP2-CAR-NK
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06358430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06358430.